Choate Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Choate Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,889	Closed	-$1.16M	–	410
2023 Q4	$1.16M	Sell	4,889 -278	-5%	-$54.7K	0.04%	164
2023 Q3	$1.01M	Buy	5,167 +58	+1%	+$11.9K	0.04%	159
2023 Q2	$1.07M	Sell	5,109 -2,711	-35%	-$539K	0.04%	136
2023 Q1	$1.58M	Buy	7,820 +1,200	+18%	+$272K	0.08%	100
2022 Q4	$1.44M	Buy	6,620 +4,458	+206%	+$974K	0.09%	98
2022 Q3	$425K	Buy	2,162 +636	+42%	+$137K	0.03%	172
2022 Q2	$327K	Buy	1,526 +328	+27%	+$80.1K	0.02%	206
2022 Q1	$340K	Buy	+1,198	New	+$369K	0.02%	232

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Choate Investment Advisors's CRL Position: Q1 2024 in Review

Choate Investment Advisors sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 4,889 shares — an estimated $1.16M sold.

Choate Investment Advisors first reported a position in CRL in Q1 2022 and held it in 8 quarters. The position peaked at $1.58M in Q1 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

Choate Investment Advisors reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
Choate Investment Advisors sold 4,889 Charles River Laboratories shares in Q1 2024, an estimated $1.16M.
Choate Investment Advisors first reported a position in Charles River Laboratories in Q1 2022 and held it in 8 quarters.
Choate Investment Advisors's Charles River Laboratories position peaked at $1.58M in Q1 2023.
676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Choate Investment Advisors's 13F filing for Q1 2024, filed 7 May 2024.